Control
Life is busy…
…HRT doesn’t have to be
Women and their doctors can rely on Femoston® for a reliable, consistent bleeding profile and well-established safety profile. 1
Femoston® & postmenopause bleeding profile
Femoston® 1mg /10mg
Estradiol / Dydrogesterone
Femoston® 2mg /10mg
Estradiol / Dydrogesterone
Demostrated bleeding control with 75% – 80% and 90% achieving regular withdrawal bleeds respectively. 2-4
Femoston® & vasomotor symptom control
Compared to the placebo, Femoston®-conti 0.5/2.5mg and 1/5mg resulted in a statistically significant greater reduction in the number of daily hot flushes by Week 4, Week 8 and Week 13.
Femoston® & endometrial protection
Across all doses, Femoston® has demonstrated endometrial protection of ≥ 98% of women using Femoston®. 1-5-6
- An adequate progestational response was confirmed by biopsy in 98% of postmenopausal women (n=275) following 26 cycles of oral HRT treatment with a range of Femoston® doses in a randomised, placebo-controlled trial: 1/5mg, 97.7% (n=96); 1/10mg, 98.9% (n=93); 2/10mg, 98.8% (n=84). Placebo, 100% (n=55).5
Study definition of adequate progestational response: histological (microscopic) appearance after treatment showing secretory changes typical of exposure to pregestogen, plus no evidence of hyperplasia or malignancy in biopsy. 5
- Femoston®-conti 0.5/2.5mg was assessed for endometrial safety in an open, multi-centre study of 290 healthy, non-hysterectomised postmenopausal women. 289 of 290 (99.7%) achieved an adequate progestational response following 1 year of treatment. 1
Reduced risk of endometrial cancer with fixed-dose combination HRT
Compared to separate oestradiol/progesterone HRT
Study conducted in the EPIC cohort concluded that there was a significant reduction in endometrial cancer risk in continuous combined HRT users compared with sequential combined HRT and oestradiol/micronised progesterone users7.
A possible explanation is that there was less compliance in oestradiol (transdermal)/ micronised progesterone (oral) users because there were two separate components to their HRT which had to be complied with7
*Oestradiol was administered transdermally while micronised progesterone was administered orally
Abbreviations: CI, confidence interval; D, dydrogesterone; E, oestradiol; EPIC, European Prospective Investigation into Cancer and Nutrition; HRT, hormone replacement therapy.
References: 1. Quereux C et al. Maturitas. 2006; 53(3):299–305; 2. Stevenson JC, et al. Maturitas. 2010;67(3):227–232 3. Femoston® 1mg/10mg Summary of Product Characteristics 4. Femoston® 2/10mg Summary of Product Characteristics 5. Ferenczy A et al. Climacteric 2002; 5(1):26–35 6. Bergeron C et al. Maturitas. 2010; 66(2):201–205 7. Panay N et al. Post Reprod Health. 2014;20:69–72
